Leerink Partnrs Comments on Merus’ Q2 2024 Earnings (NASDAQ:MRUS)

Merus (NASDAQ:MRUSFree Report) – Leerink Partnrs issued their Q2 2024 earnings per share (EPS) estimates for Merus in a research note issued on Monday, February 5th. Leerink Partnrs analyst A. Berens expects that the biotechnology company will earn ($0.81) per share for the quarter. The consensus estimate for Merus’ current full-year earnings is ($2.61) per share.

MRUS has been the subject of several other research reports. StockNews.com upgraded Merus from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. Canaccord Genuity Group started coverage on Merus in a report on Thursday, November 2nd. They set a “buy” rating and a $45.00 price objective on the stock. Stifel Nicolaus decreased their target price on Merus from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, October 24th. Needham & Company LLC reiterated a “buy” rating and issued a $42.00 price objective on shares of Merus in a research report on Monday, December 4th. Finally, Canaccord Genuity Group assumed coverage on Merus in a research report on Thursday, November 2nd. They set a “buy” rating and a $45.00 target price for the company. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $44.60.

View Our Latest Research Report on MRUS

Merus Stock Performance

NASDAQ:MRUS opened at $40.06 on Wednesday. Merus has a 1 year low of $16.06 and a 1 year high of $40.74. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of -10.65 and a beta of 1.04. The business has a fifty day moving average of $30.16 and a 200-day moving average of $25.50.

Insider Activity

In other news, COO Peter B. Silverman sold 22,386 shares of Merus stock in a transaction on Friday, December 15th. The stock was sold at an average price of $25.00, for a total value of $559,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 23,076 shares of company stock valued at $576,852. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Merus

Institutional investors have recently made changes to their positions in the stock. BluePath Capital Management LLC bought a new position in Merus during the third quarter worth about $33,000. Quadrant Capital Group LLC lifted its holdings in Merus by 37.7% during the fourth quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 343 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Merus by 142.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 867 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in Merus by 107.4% during the second quarter. BNP Paribas Arbitrage SA now owns 1,811 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 938 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Merus by 871.4% in the second quarter. JPMorgan Chase & Co. now owns 1,564 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 1,403 shares in the last quarter. 90.68% of the stock is owned by institutional investors and hedge funds.

Merus Company Profile

(Get Free Report)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Further Reading

Earnings History and Estimates for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.